Drugs / Immunoglobulin
Immunoglobulin
also known as
IVIg · Hizentra · Immunoglobulin subcutaneous (human) 20% liquid, Hizentra · intravenous immune globulin · PRIVIGEN
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT07561125 | Apr 2026 → Sep 2027 expected | bronchopulmonary dysplasia | International Peace Maternity and Child Health Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06925360 | Apr 2025 → Dec 2027 expected | bronchopulmonary dysplasia | International Peace Maternity and Child Health Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT02782897 | Jun 2016 → Dec 2017 | intracerebral hemorrhage | Wei Wang | Unknown | No outcome recorded |
| Phase 2 | NCT02343211 | Nov 2013 → Jun 2016 | paraneoplastic neurologic syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT03560011 | Apr 2019 → Jan 2021 | idiopathic nephrotic syndrome | Assistance Publique - Hôpitaux de Paris | Suspended | No outcome recorded |
| Phase 2/3 | NCT03211065 | Jul 2017 → Nov 2019 | acquired immunodeficiency | Rochester General Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01561053 | Apr 2012 → Mar 2018 | Alzheimer disease | Grifols, S.A. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT03492710 | Apr 2019 | inborn error of immunity | Green Cross Corporation | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02834468 | Jun 2016 → Jul 2018 | thrombocytopenia due to immune destruction | Shandong University | Unknown | No outcome recorded |
| Phase 3 | NCT02398994 | Mar 2015 → Mar 2016 | neuromyelitis optica, transverse myelitis | Guy's and St Thomas' NHS Foundation Trust | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01349270 | Jun 2004 → Dec 2013 | demyelinating polyneuropathy | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05520892 | Oct 2022 → Aug 2025 overdue | primary thrombocytopenia | Fujian Medical University Union Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT02990403 | Oct 2014 → Jun 2017 | pregnancy loss, recurrent, 4 | Shanghai First Maternity and Infant Hospital | Unknown | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 0 | NCT02271165 Comparator | Nov 2014 → Mar 2017 | dermatomyositis | Thomas Jefferson University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01895127 Comparator | Nov 2013 → Apr 2016 | transplant rejection | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00268788 Comparator | Aug 2005 → Feb 2008 | multifocal motor neuropathy | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT03200561 Comparator | Oct 2013 → Dec 2020 | Kawasaki disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04589299 Comparator | Jun 2020 → Dec 2030 expected | polyneuropathy, inflammatory demyelinating, chronic | University of Aarhus | Recruiting | No outcome recorded |
| — | NCT01554930 Comparator | May → Nov 2010 | hand, foot and mouth disease | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
Press releases naming this drug 51 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | immunoglobulin | “intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months)” NCT02834468 ↗ |
| Known as | Hizentra | “Immunoglobulin (HIZENTRA) subcutaneously 0.54 g/kg/week for 26 weeks.” NCT04589299 ↗1“Drug: Immunoglobulin (Hizentra)” NCT02271165 ↗ |
| Known as | Immunoglobulin subcutaneous (human) 20% liquid, Hizentra | “Immunoglobulin subcutaneous (human) 20% liquid, Hizentra” NCT02271165 ↗ |
| Known as | intravenous immune globulin | “intravenous immune globulin (IVIG)” NCT05520892 ↗ |
| Known as | IVIg | “Intravenous immunoglobulin (IVIG) is often used as second-line treatment in steroid-unresponsive central nervous system demyelination” NCT02398994 ↗4“intravenous immunoglobulin (IVIg) could help to reduce symptoms.” PMID 38353301 ↗ Feb 2024 “human intravenous immunoglobulin (IVIg)” NCT02343211 ↗ “intravenous immune globulin (IVIG)” NCT05520892 ↗ “Intravenous immunoglobulin (IVIg)” NCT04381936 ↗ |
| Known as | PRIVIGEN | “Immunoglobulin (PRIVIGEN) intravenously 2 g/kg/4week for 26 weeks.” NCT04589299 ↗ |
| Modality | Protein / enzyme biologic | “Immunoglobulin preparations are now available for subcutaneous use as IgG replacement therapy.” NCT00268788 ↗ |
| Route | Subcutaneous | “Subcutaneous Ig given twice a week.” NCT00268788 ↗ |